Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC

Among the 47 Japanese patients who received brigatinib at the standard dose after progression from alectinib with or without history of crizotinib use, objective response rate (ORR) and disease control rate (DCR) were 34% (16 of 47) and 79% (37 of 47), respectively, with a median progression-free survival (PFS) of 7.3 months. READ ARTICLE

Journal of Thoracic Oncology DOI: 10.1016/J.JTHO.2020.11.023

Authors: Lianxi Song, Qinqin Xu, Analyn Lizaso, Yongchang Zhang,

EditorialKirk SmithMarch 1, 2021Alectinib progression, Crizotinib progression, Brigatinib